MA41124A - Compositions en suspension à libération prolongée à rétention gastrique - Google Patents

Compositions en suspension à libération prolongée à rétention gastrique

Info

Publication number
MA41124A
MA41124A MA041124A MA41124A MA41124A MA 41124 A MA41124 A MA 41124A MA 041124 A MA041124 A MA 041124A MA 41124 A MA41124 A MA 41124A MA 41124 A MA41124 A MA 41124A
Authority
MA
Morocco
Prior art keywords
extended
gastric retention
suspension compositions
release suspension
release
Prior art date
Application number
MA041124A
Other languages
English (en)
Inventor
Paras P Jain
Suchitra Kaushik
Ashish Kumar
Vinay Kumar
Romi Barat Singh
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of MA41124A publication Critical patent/MA41124A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
MA041124A 2014-12-05 2015-04-30 Compositions en suspension à libération prolongée à rétention gastrique MA41124A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3553DE2014 2014-12-05

Publications (1)

Publication Number Publication Date
MA41124A true MA41124A (fr) 2017-10-10

Family

ID=56091086

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041124A MA41124A (fr) 2014-12-05 2015-04-30 Compositions en suspension à libération prolongée à rétention gastrique

Country Status (10)

Country Link
US (1) US20180008539A1 (fr)
EP (1) EP3226839A4 (fr)
JP (1) JP2017536404A (fr)
AU (1) AU2015356781A1 (fr)
BR (1) BR112017011922A2 (fr)
CA (1) CA2969820A1 (fr)
MA (1) MA41124A (fr)
MX (1) MX2017007299A (fr)
RU (1) RU2017123366A (fr)
WO (1) WO2016087952A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012011022A (es) 2010-03-24 2013-02-26 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas.
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
CN109922801B (zh) * 2016-09-09 2023-07-18 库蒂斯制药公司 甲硝唑和巴氯芬的混悬剂和稀释剂
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
WO2019126214A1 (fr) 2017-12-18 2019-06-27 Tris Pharma, Inc. Composition pharmaceutique comprenant des systèmes formant un radeau de rétention gastrique de ghb à libération de médicament par impulsions de déclenchement
EP3740188A1 (fr) * 2017-12-18 2020-11-25 Tris Pharma, Inc. Compositions pharmaceutiques comprenant un système formant un réseau polymère d'interpénétration flottant
JP2021506984A (ja) * 2017-12-18 2021-02-22 トリス・フアルマ・インコーポレーテツド トリガーパルス薬物放出を有する胃内滞留型raft形成システムを含む放出調節薬物粉末組成物
IL275312B1 (en) * 2017-12-18 2024-05-01 Tris Pharma Inc GHB pharmacy preparations containing a system that creates a floating integrated penetrating polymer network
JP7273976B2 (ja) 2018-09-21 2023-05-15 アムニール コンプレックス プロダクツ リサーチ エルエルシー トリヘキシフェニジルを含む徐放性組成物
KR20200053746A (ko) 2018-11-09 2020-05-19 (주)아모레퍼시픽 졸-겔 조성물
KR20210094513A (ko) 2018-11-19 2021-07-29 재즈 파마슈티칼즈 아일랜드 리미티드 알코올-내성 약물 제형
WO2020131780A1 (fr) * 2018-12-18 2020-06-25 Ddp Specialty Electronics Materials Us, Inc. Composition à libération prolongée comprenant une méthylcellulose
EP3897731A1 (fr) * 2018-12-18 2021-10-27 DDP Specialty Electronic Materials US, Inc. Composition à libération prolongée comprenant une éthylcellulose
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
CA3139217A1 (fr) 2019-05-14 2020-11-19 Clexio Biosciences Ltd. Traitement de symptomes nocturnes et de l'akinesie matinale chez des sujets atteints de la maladie de parkinson
US11654124B2 (en) 2019-07-29 2023-05-23 Amneal Pharmaceuticals Llc Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US10792262B1 (en) * 2019-07-29 2020-10-06 Saol International Limited Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
CN112516159B (zh) * 2020-12-03 2022-06-17 爱希(北京)国际咨询有限公司 一种含有硝酸盐的组合物、胃漂浮剂及制备方法和应用
US11154505B1 (en) 2021-02-03 2021-10-26 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising trihexyphenidyl
WO2022195476A1 (fr) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Dispositifs de rétention gastrique pour l'évaluation d'états intragastriques
CN112933055B (zh) * 2021-03-23 2023-01-13 安徽九华华源药业有限公司 帕利哌酮胃滞留片及其制备方法
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
WO2024030936A1 (fr) * 2022-08-02 2024-02-08 Nutrition & Biosciences Usa 1, Llc Composition à base d'alginate à libération modifiée

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
ATE306250T1 (de) * 1998-12-23 2005-10-15 Alza Corp Dosierungsformen, die poröse partikel enthalten
JP2004002320A (ja) * 2002-03-04 2004-01-08 Medorekkusu:Kk 生体内で相転移する液状マトリックスおよび液状経口製剤
ATE419840T1 (de) * 2002-04-09 2009-01-15 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
WO2006115834A1 (fr) * 2005-04-20 2006-11-02 Merck & Co., Inc. Antagonistes des recepteurs de l'angiotensine ii
ES2350029T3 (es) * 2007-03-02 2011-01-17 Farnam Companies, Inc. Pellets de liberación sostenida que comprenden un material tipo cera.
WO2008122993A1 (fr) * 2007-04-09 2008-10-16 Panacea Biotec Limited Formulation de microparticules enrobées à libération contrôlée
KR20100016445A (ko) * 2007-04-11 2010-02-12 바이오마린 파머수티컬 인크. 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법
WO2010011466A2 (fr) * 2008-06-27 2010-01-28 Otonomy, Inc. Compositions de modulation du snc à libération contrôlée et procédés de traitement des troubles otiques
WO2011107855A2 (fr) * 2010-03-04 2011-09-09 Torrent Pharmaceuticals Limited Forme dosifiée sous forme de suspension liquide à libération prolongée pour une administration par voie orale
EP3137060B2 (fr) * 2014-05-01 2023-12-20 Sun Pharmaceutical Industries Ltd Compositions en suspension à libération prolongée

Also Published As

Publication number Publication date
WO2016087952A1 (fr) 2016-06-09
EP3226839A4 (fr) 2018-07-11
EP3226839A1 (fr) 2017-10-11
MX2017007299A (es) 2017-08-25
US20180008539A1 (en) 2018-01-11
RU2017123366A (ru) 2019-01-10
RU2017123366A3 (fr) 2019-01-10
CA2969820A1 (fr) 2016-06-09
JP2017536404A (ja) 2017-12-07
AU2015356781A1 (en) 2017-06-29
BR112017011922A2 (pt) 2018-01-16

Similar Documents

Publication Publication Date Title
MA41124A (fr) Compositions en suspension à libération prolongée à rétention gastrique
DK3731771T3 (da) V462033dk00
MA44702A (fr) Compositions de suspension à libération prolongée
DE202018003363U8 (de) Handgelenkssphygmomanometer
CL2018000524S1 (es) Golilla
DK3351526T3 (da) Diisopentylterephthalat
DK3568655T3 (da) Rekuperator
DK3571580T3 (da) Load-logical-and-shift-guarded-instruktion
KR20180084876A (ko) 내플라즈마성 부재
DK3438103T3 (da) Griseofulvinforbindelse
MA45305A (fr) Suspension améliorée
DK3612237T3 (da) Genterapi
DK3568506T3 (da) Offeranode
DK3576686T3 (da) Brokbind
DK3352735T3 (da) Olanzapinformuleringer med langvarig frigivelse
DK3676276T3 (da) Spirothietannukleosider
DK3395159T3 (da) Ballepresse
DK3576718T3 (da) Pastil
FI11704U1 (fi) Liittopuujärjestely
DK3510051T3 (da) Carboxylalkylchitosan
DK3642136T3 (da) Veksellad
ES1205411Y (es) Maleta-Gaveta
ES1198359Y (es) Columbario
FI11529U1 (fi) Ontelolaatan kannake
DK3645955T3 (da) Buffertank